GSK (GLAXF) Total Debt per Share: $6.32 (As of Mar. 2026)


GLAXF GSK PLC GLAXF
69 GF Score
Price $27.00
GF Value $21.82
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is GSK Total Debt per Share?

GSK GLAXF +4.77% 69 Total Debt per Share is $6.32 as of Mar. 2026. GuruFocus rates GLAXF with a GF Score™ of 69/100 and a GF Value™ of $21.82 (Modestly Overvalued). The stock has 1 warning sign investors should review.

$6.32 (As of Mar. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. GSK's Total Debt Per Share for the quarter that ended in Mar. 2026 was $6.32.

GSK Total Debt per Share Historical Data

* Premium members only.

The historical data trend for GSK's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GSK Total Debt per Share Chart

GSK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.99 6.24 5.62 5.26 5.91

GSK Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.83 5.82 5.96 5.91 6.32
GLAXF
69GF Score
GSK PLC GLAXF
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GSK Total Debt per Share Calculation

GSK's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(19,689+4,032)/4,013
=5.91

GSK's Total Debt Per Share for the quarter that ended in Mar. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(18,683+6,725)/4,020
=6.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of $6.32 mean?
GSK (GLAXF) has a Total Debt per Share of $6.32 as of Mar. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on GSK and its competitors.
Is GSK's Total Debt per Share too high?
GSK's current Total Debt per Share is $6.32. Overall, GSK has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's Total Debt per Share compare to LLY and JNJ?
GSK's Total Debt per Share of $6.32 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Drug Manufacturers company?
A good Total Debt per Share depends on the Drug Manufacturers industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on GSK and its competitors. GSK's current Total Debt per Share is $6.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (GLAXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.82, compared to a current price of $27.00 — trading 23.7% above its estimated fair value. The current Total Debt per Share is $6.32. GSK's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For GSK (GLAXF), the current Total Debt per Share is $6.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GSK (GLAXF) Overvalued in 2026?

Based on GuruFocus' analysis, GSK stock appears to be overvalued. The current stock price of $27.00 is trading 23.7% above its estimated GF Value™ of $21.82. GuruFocus considers GSK to be Modestly Overvalued.

Key valuation signals for GLAXF:

  • Total Debt per Share: $6.32
  • GF Value™: $21.82 vs. price of $27.00 (23.7% above fair value)
  • GF Score™: 69/100 with 1 warning sign

No single metric tells the full story. See the GLAXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GSK Business Description

Address 79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
69GF Score

Get the complete analysis for GLAXF

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.00
Price
$21.82
GF Value